相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
Christophe Willekens et al.
HAEMATOLOGICA (2016)
Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
Christophe Willekens et al.
HAEMATOLOGICA (2016)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Daisuke Araki et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
Avichai Shimoni et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
Xiao-Dong Mo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification
Yu Wang et al.
BLOOD (2014)
Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation
J-H Yoon et al.
BONE MARROW TRANSPLANTATION (2014)
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center
Ya-Zhen Qin et al.
LEUKEMIA RESEARCH (2014)
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Eric Jourdan et al.
BLOOD (2013)
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
Hong-Hu Zhu et al.
BLOOD (2013)
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Roland B. Walter et al.
BLOOD (2013)
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Chen-Hua Yan et al.
BLOOD (2012)
Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
John A. Liu Yin et al.
BLOOD (2012)
Superior Graft-versus-Leukemia Effect Associated with Transplantation of Haploidentical Compared with HLA-Identical Sibling Donor Grafts for High-Risk Acute Leukemia: An Historic Comparison
Yu Wang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
A >= 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse
Steven Lane et al.
LEUKEMIA & LYMPHOMA (2008)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen et al.
BLOOD (2007)
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors
M. Weisser et al.
LEUKEMIA (2007)
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
Frederick R. Appelbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation
DP Lu et al.
BLOOD (2006)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)
H Leroy et al.
LEUKEMIA (2005)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia:: A survey of the German Acute Myeloid Leukemia Intergroup
RF Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia:: a single center study
M Mitterbauer et al.
LEUKEMIA & LYMPHOMA (2004)